Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Jasper Therapeutics, Inc. JSPR

Healthcare  —  Biotechnology
0.61 0.02 3.39% as of 25 Sep
Market cap
$19.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Jasper Therapeutics, Inc. (JSPR) Business Profile

Updated before January 2025

Company Overview

Jasper Therapeutics, Inc. (NASDAQ: JSPR) is a clinical-stage biotechnology company focused on developing innovative therapies for hematopoietic cell transplantation (HCT) and other immune-related diseases. Founded in 2019 and headquartered in Redwood City, California, Jasper Therapeutics was established with the mission of transforming the field of hematopoietic stem cell transplantation by addressing the limitations of current conditioning regimens. The company was co-founded by Dr. Judith Shizuru, a renowned expert in stem cell biology, and Dr. Irving Weissman, a pioneer in regenerative medicine. Jasper Therapeutics is led by a team of seasoned executives, including Chief Executive Officer Ronald Martell, who brings decades of experience in the biopharmaceutical industry.

Core Business Segments

Conditioning Agents for Hematopoietic Cell Transplantation

Jasper Therapeutics’ flagship product candidate is JSP191, a monoclonal antibody designed to replace traditional chemotherapy and radiation-based conditioning regimens for hematopoietic cell transplantation. JSP191 selectively targets CD117 (c-Kit), a receptor expressed on hematopoietic stem cells, enabling safer and more effective transplantation procedures. This product is being developed for multiple indications, including:

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndromes (MDS)
  • Severe Combined Immunodeficiency (SCID)

Gene Therapy and Immune Modulation

In addition to its focus on HCT, Jasper Therapeutics is exploring the use of JSP191 in gene therapy applications. By enabling safer conditioning, JSP191 has the potential to expand the accessibility of gene therapies for a variety of genetic disorders. The company is also investigating the broader immunomodulatory properties of JSP191 for treating autoimmune diseases and other immune-related conditions.

Research and Development Services

Jasper Therapeutics collaborates with academic institutions, research organizations, and biopharmaceutical companies to advance its pipeline. The company provides expertise in preclinical and clinical development, leveraging its proprietary technologies to accelerate innovation in the field of regenerative medicine.

Business Model

Jasper Therapeutics operates on a business model centered around innovation, strategic partnerships, and clinical development. The company generates revenue primarily through research collaborations, licensing agreements, and milestone payments. By focusing on a niche market with high unmet medical needs, Jasper Therapeutics aims to establish itself as a leader in the field of hematopoietic cell transplantation and immune modulation. The company’s approach integrates cutting-edge science with a patient-centric focus, ensuring that its therapies address both clinical efficacy and safety.

Strategic Direction

Jasper Therapeutics is committed to advancing its pipeline of innovative therapies while expanding its market presence. Key strategic priorities include:

  • Pipeline Expansion: The company plans to explore additional indications for JSP191, including autoimmune diseases and other immune-related disorders.
  • Global Market Penetration: Jasper Therapeutics aims to establish partnerships with international organizations to bring its therapies to patients worldwide.
  • Sustainability Goals: The company is dedicated to minimizing its environmental footprint by adopting sustainable practices in its research and manufacturing processes.
  • New Product Development: Jasper Therapeutics is actively investing in research to identify novel therapeutic targets and develop next-generation conditioning agents.

Competitive Landscape

Jasper Therapeutics operates in a competitive and rapidly evolving market. Key competitors include:

  • Magenta Therapeutics: Focused on developing novel conditioning regimens for stem cell transplantation.
  • bluebird bio: A leader in gene therapy and hematopoietic stem cell transplantation.
  • Sangamo Therapeutics: Specializes in genomic medicine and gene editing technologies.
  • Fate Therapeutics: Develops cellular immunotherapies for cancer and immune disorders.

Despite the competition, Jasper Therapeutics differentiates itself through its unique approach to conditioning and its focus on addressing the limitations of traditional transplantation methods.

Risk Factors

Jasper Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The company’s therapies must undergo rigorous clinical trials and regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: Jasper Therapeutics relies heavily on the success of JSP191, making it vulnerable to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply of raw materials and manufacturing components.
  • Financial Constraints: As a clinical-stage company, Jasper Therapeutics may require additional funding to support its research and development activities.

Recent Developments

Jasper Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: The company announced positive interim results from its Phase 1/2 clinical trials of JSP191, demonstrating its safety and efficacy in patients with AML and MDS.
  • Partnerships: Jasper Therapeutics entered into a collaboration with a leading gene therapy company to explore the use of JSP191 in gene editing applications.
  • Corporate Milestones: The company successfully completed a public offering, raising funds to support its ongoing research and development efforts.

Investment Considerations

Strengths

  • Innovative Pipeline: Jasper Therapeutics is at the forefront of developing next-generation conditioning agents for hematopoietic cell transplantation.
  • Experienced Leadership: The company is led by a team of industry veterans with a proven track record in biotechnology.
  • High Unmet Medical Need: Jasper Therapeutics addresses critical gaps in the treatment of hematologic malignancies and immune-related diseases.

Risks

  • Clinical and Regulatory Uncertainty: The success of JSP191 depends on the outcome of clinical trials and regulatory approvals.
  • Financial Risk: As a pre-revenue company, Jasper Therapeutics may face challenges in securing sufficient funding.
  • Competitive Pressure: The company operates in a highly competitive market with established players.

Conclusion

Jasper Therapeutics, Inc. is a pioneering biotechnology company with a strong focus on transforming hematopoietic cell transplantation and immune modulation. With its innovative pipeline, strategic partnerships, and commitment to addressing unmet medical needs, Jasper Therapeutics is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage companies before making investment decisions. As the company continues to advance its pipeline and expand its market presence, it has the potential to become a leader in the field of regenerative medicine.